Intranasal immunization with HRSV prefusion F protein and CpG adjuvant elicits robust protective effects in mice

Hu Ren(National Institute for Viral Disease Control and Prevention), Wenbo Xu(Shenyang Institute of Automation), Jinyuan Guo(National Institute for Viral Disease Control and Prevention), Hongtu Liu(National Institute for Viral Disease Control and Prevention), Lei Cao(Chinese Academy of Sciences), Hai Li(Shanghai East Hospital), Yan Zhang(Memorial Sloan Kettering Cancer Center), Zhan Wang(Zhejiang Lab), Yangzi Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College)
Vaccine
October 14, 2022
10.1016/j.vaccine.2022.09.071
Cited by 9

Related Papers

A Novel Coronavirus from Patients with Pneumonia in China, 2019
|New England Journal of Medicine|2020|30.5k
Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding
|The Lancet|2020|12.6k
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
|Nature|2020|1.2k
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
|Cell|2020|802
An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of Hand Foot and Mouth Disease in Fuyang city of China
|Virology Journal|2010|473